ENLIGHTEN-2: Eloralintide Phase 3 trial (NCT07282600)
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Once Weekly Eloralintide in Adult Participants With Obesity or Overweight, and Type 2 Diabetes
Registry record checked
At a glance
- Phase
- Phase 3
- Status
- Recruiting
- Enrolment
- 1,035
- estimated
- Start
- 15 Dec 2025 (actual)
- Primary completion
- Jan 2028 (estimated)
- Sponsor
- Eli Lilly and Company
Design
Arms and doses
| Arm | Type | Interventions | Description |
|---|---|---|---|
| Eloralintide Dose 1 | Experimental | Drug: Eloralintide | Participants will receive eloralintide subcutaneously (SC) |
| Eloralintide Dose 2 | Experimental | Drug: Eloralintide | Participants will receive eloralintide SC |
| Eloralintide Dose 3 | Experimental | Drug: Eloralintide | Participants will receive eloralintide SC |
| Eloralintide Dose 4 | Experimental | Drug: Eloralintide | Participants will receive eloralintide SC |
| Placebo | Placebo comparator | Drug: Placebo | Participants will receive placebo SC |
Endpoints
Primary endpoint
| Measure | Time frame |
|---|---|
| Percent Change from Baseline in Body Weight | Baseline, Week 64 |
Endpoints
Key secondary endpoints
The first secondary outcomes listed on the registry record.
| Measure | Time frame |
|---|---|
| Percent Change from Baseline in Total Body Fat Mass | Baseline, Week 64 |
| Change from Baseline in Waist Circumference | Baseline, Week 64 |
| Change from Baseline in Hemoglobin A1c (HbA1c) | Baseline, Week 64 |
| Percent Change in Baseline in Triglycerides | Baseline, Week 64 |
| Change from Baseline in Systolic Blood Pressure | Baseline, Week 64 |
| Change from Baseline in Body Mass Index (BMI) | Baseline, Week 64 |
| Percent Change from Baseline in High Sensitivity C-Reactive Protein (hsCRP) | Baseline, Week 64 |
| Percent Change from Baseline in Fasting Insulin | Baseline, Week 64 |
| Change in Medication Use | Baseline through Week 64 |
| Change from Baseline in Estimated Glomerular Filtration Rate (eGFR) | Baseline, Week 64 |
| Change from Baseline in Short Form-36 (SF-36 v2) Score | Baseline, Week 64 |
| Change from Baseline in EQ-5D-5L Score | Baseline, Week 64 |
Eligibility
Who could enrol
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- Not stated
Results
Results
No results posted on ClinicalTrials.gov as of 2 Oct 2026.
Sources
- 1A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Once Weekly Eloralintide in Adult Participants With Obesity or Overweight, and Type 2 DiabetesClinicalTrials.gov (U.S. National Library of Medicine) · registry recordclinicaltrials.govAccessed 2 Oct 2026
Found an error? Report a correction.